GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » Forward Dividend Yield %

XTL Biopharmaceuticals (XTAE:XTLB) Forward Dividend Yield % : 0.00% (As of Jun. 05, 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals Forward Dividend Yield %?

As of today (2024-06-05), the Forward Annual Dividend Yield of XTL Biopharmaceuticals is 0.00%.

As of today (2024-06-05), the Trailing Annual Dividend Yield of XTL Biopharmaceuticals is 0.00%.

XTAE:XTLB's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.665
* Ranked among companies with meaningful Forward Dividend Yield % only.

XTL Biopharmaceuticals's Dividends per Share for the three months ended in Mar. 2024 was ₪0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of XTL Biopharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, XTL Biopharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XTL Biopharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Forward Dividend Yield % falls into.


XTL Biopharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

XTL Biopharmaceuticals  (XTAE:XTLB) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

XTL Biopharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

XTL Biopharmaceuticals (XTAE:XTLB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » Forward Dividend Yield %
Comparable Companies
XTAE:CANF XTAE:PPBT XTAE:CBI XTAE:MTLF XTAE:KDST XTAE:BOLT XTAE:PLNT XTAE:HDST-M XTAE:DNA XTAE:GFC-M OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
XTLB:USA H2K2:Germany
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
Website
https://www.xtlbio.com
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.